Christophe Van Steenkiste onbezoldigd gastprofessor

Publicaties Christophe Van Steenkiste

A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection : clinical outcomes with microbiome and metabolome correlates of response

Bron
Clinical infectious diseases - ISSN 1058-4838- (2024) p. 1-11
Auteur(s)
    Pablo C. Okhuysen, Mayur S. Ramesh, Thomas Louie, Nino Kiknadze, Julian Torre-Cisneros, Claudia Murta de Oliveira, Christophe Van Steenkiste, Alena Stychneuskaya, Kevin W. Garey, Julia Garcia-Diaz, Jianling Li, Esther Duperchy, Betty Y. Chang, Juthamas Sukbuntherng, Jose G. Montoya, Lori Styles, Fong Clow, Danelle James, Erik R. Dubberke, Mark Wilcox

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Bron
The New England journal of medicine - ISSN 0028-4793-390:6 (2024) p. 497-509
Auteur(s)
    Stephen A. Harrison, Pierre Bedossa, Cynthia D. Guy, Jörn M. Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E. Moussa, Guy W. Neff, Mary E. Rinella, Quentin M. Anstee, Manal F. Abdelmalek, Zobair Younossi, Seth J. Baum, Sven Francque, Michael R. Charlton, Philip N. Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M. Pericàs, Rashmee Patil, Arun J. Sanyal, Mazen Noureddin, Meena B. Bansal, Naim Alkhouri, Laurent Castera, Madhavi Rudraraju, Vlad Ratziu, Christophe Van Steenkiste

The role of Helicobacter suis, Fusobacterium gastrosuis, and the pars oesophageal microbiota in gastric ulceration in slaughter pigs receiving meal or pelleted feed

Bron
Veterinary research - ISSN 1297-9716-55:1 (2024) p. 1-15
Auteur(s)
    Emily Taillieu, Steff Taelman, Sofie De Bruyckere, Evy Goossens, Ilias Chantziaras, Christophe Van Steenkiste, Peter Yde, Steven Hanssens, Dimitri De Meyer, Wim Van Criekinge, Michiel Stock, Dominiek Maes, Koen Chiers, Freddy Haesebrouck

The Role of Abdominal Surgery in Refractory Immune Checkpoint Inhibitor Enterocolitis: A Case Report

Bron
Case Reports in Oncology - ISSN 1662-6575-16:1 () p. 453-460
Auteur(s)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Bron
The lancet : international edition - ISSN 0140-6736-402:10408 () p. 1133-1146
Auteur(s)
    Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, Christophe Van Steenkiste